Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis

被引:242
作者
Saaristo, A
Karpanen, T
Alitalo, K
机构
[1] Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland
[2] Univ Helsinki, Haartman Inst, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland
关键词
breast cancer; metastasis; lymphatic vessels; VEGF; VEGF-C;
D O I
10.1038/sj.onc.1203969
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is a constant requirement for vascular supply in solid tumors. Tumor-associated neovascularization allows the tumor cells to express their critical growth advantage. Axillary lymph node status is the most important prognostic factor in operable breast cancer, and experimental and clinical evidence suggests that the process of metastasis is also angiogenesis-dependent. Various angiogenic growth factors and cytokines induce neovascularization in tumors, namely members of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) gene families. A strong correlation has been found between VEGF expression and increased tumor microvasculature, malignancy, and metastasis in breast cancer, Anti-angiogenic therapy approaches offer a new promising anti-cancer strategy and a remarkably diverse group of over 20 such drugs is currently undergoing evaluation in clinical trials.
引用
收藏
页码:6122 / 6129
页数:8
相关论文
共 114 条
[1]   Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[2]   Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis [J].
Adams, RH ;
Wilkinson, GA ;
Weiss, C ;
Diella, F ;
Gale, NW ;
Deutsch, U ;
Risau, W ;
Klein, R .
GENES & DEVELOPMENT, 1999, 13 (03) :295-306
[3]  
APRELIKOVA O, 1992, CANCER RES, V52, P746
[4]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[5]  
Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014
[6]   VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells [J].
Asahara, T ;
Takahashi, T ;
Masuda, H ;
Kalka, C ;
Chen, DH ;
Iwaguro, H ;
Inai, Y ;
Silver, M ;
Isner, JM .
EMBO JOURNAL, 1999, 18 (14) :3964-3972
[7]   Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal [J].
Benjamin, LE ;
Keshet, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) :8761-8766
[8]  
Brekken RA, 1998, CANCER RES, V58, P1952
[9]  
BREM SS, 1978, CANCER, V41, P239, DOI 10.1002/1097-0142(197801)41:1<239::AID-CNCR2820410133>3.0.CO
[10]  
2-X